Meldonium vs Semax
Moderate Research vs Well Studied
monitor Mechanism-based · 51% Both Meldonium and Semax can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Meldonium Semax
Weight 146.19 Da 813.93 Da
Half-life ~4-6 hours 0.5-2 hours
Chain — 7 amino acids
Type Hydrazinium derivative (C6H14N2O2) ACTH(4-10) synthetic analog
Key Benefits
Meldonium
01 Cardioprotective effects through metabolic optimization under ischemic conditions
02 Shifts cardiac energy metabolism from fatty acid oxidation to more oxygen-efficient glucose oxidation
03 Reduces accumulation of toxic fatty acid intermediates (long-chain acylcarnitines) in heart tissue
04 Promotes nitric oxide synthesis and endothelial function via GBB accumulation
05 May improve exercise capacity and reduce recovery time through enhanced glucose utilization
06 Used as adjunctive cardiac protection during anabolic steroid cycles to mitigate androgen-induced cardiotoxicity
07 Well-established safety profile in Eastern European clinical use spanning over 30 years
Semax
01 Rapid brain delivery via intranasal route
02 Rapidly increases BDNF levels
03 Extensive clinical research in Russia
04 Easy self-administration
05 Modulates dopamine and serotonin systems
06 Neuroprotective effects
Dosing Protocols
Meldonium
500-1000 mg/day / Once or twice daily (oral)
Semax
300-600mcg per dose (up to 1000mcg for intensive use) / 1-2x daily (morning recommended for cognitive boost)
Research protocol 500-750mcg 1x daily
Intensive protocol 750-1000mcg 1-2x daily
Side Effects
Meldonium
Mild gastrointestinal discomfort (nausea, dyspepsia, or stomach upset -- typically transient and dose-dependent)
Occasional heartburn or acid reflux, especially at higher doses or when taken on an empty stomach
Semax
Mild nasal discomfort (nasal route)
Possible nasal sensation upon administration
Contraindications
Known hypersensitivity to meldonium or any excipients
Pregnancy or breastfeeding (insufficient safety data)
Individuals under 18 years of age
Severe hepatic or renal impairment (limited pharmacokinetic data in these populations)
Increased intracranial pressure (listed as a contraindication in some regional prescribing information)
Pregnancy or breastfeeding
Known peptide allergies
Do not exceed 4-week continuous use without medical supervision
Research Evidence
Meldonium Semax
Status Moderate Research Well Studied
References 4 studies 5 studies
Latest 2016 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.